Special Issue "Cancer Immunology: From Molecular Mechanisms to Therapeutic Opportunities"
Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 42062
Interests: IL-33 pathway in cancer; eosinophils in tumor microenvironment; type I interferons pathways in cancer; tumor mouse models; organs-on-chip systems
Interests: cancer immunology; immunotherapy; clinical trials
Special Issues, Collections and Topics in MDPI journals
Immune cells are important components of the tumor microenvironment, where they play a prominent role in favoring or contrasting cancer progression through direct and indirect activities. Cancer immunology is a growing field that investigates the complex mechanisms and interactions between immune and cancer cells with the aim of identifying therapeutic targets for immunotherapy-based approaches. This Special Issue of Cells will present research articles and reviews that cover the scope of tumor immunology. The articles should focus on cellular and molecular mechanisms promoting or hampering immune responses during cancer progression and the suppression of immunity by malignant cells. Furthermore, this Special Issue aims to provide clinical and experimental evidence on how such mechanisms may be translated to immunotherapy and combined therapeutic approaches. All scientists working in these fields are cordially invited to submit their manuscripts.
We are looking forward to your contributions to this Special Issue.
Dr. Fabrizio Mattei
Dr. Carlos Alfaro
Prof. Yona Keisari
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune cells in cancer
- cancer stem cells
- molecular pathways in cancer
- tumor microenvironment
- tumor mouse models
- cytokines, cytokine receptors
- chemokines, chemokine receptors
- exosomes and cancer
- tumor suppressor genes
- oncolytic viruses
- tumor vaccines
- immune checkpoints inhibitors
- combination therapies
- novel biomarkers
- cancer genomics
- translational and clinical research
- drug repurposing
- cancer metastasis
- mechanisms of carcinogenesis
- advanced in vitro cancer models
- advanced in vivo models for translational research
- inflammation and cancer
- immunodeficiencies and cancer
- intratumor heterogeneity
- resistance to conventional therapies
- therapeutic targets in cancer
- cell-based strategies
- anti-tumor immunity
- immunomodulation and targeted therapies